Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for *MLL*-rearranged leukemia

Kimberley A Hoeksema¹
Aarthi Jayanthan¹
Todd Cooper²
Lia Gore³
Tanya Trippett⁴
Jessica Boklan⁶
Robert J Arceci⁵
Aru Narendran¹

¹Division of Pediatric Oncology, Alberta Children's Hospital, Calgary, AB, Canada; ²Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA; ³Center for Cancer and Blood Disorders, Children's Hospital, University of Colorado Denver, Aurora, CO, USA; ⁴Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ⁵Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA; ⁶Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA

Correspondence: Aru Narendran
Division of Pediatric Oncology, Alberta Children's Hospital, 2888 Shaganappi Trail NW, Calgary, Alberta T3B 6A8, Canada
Tel +1 403 210 6418
Fax +1 403 270 8243
Email a.narendran@ucalgary.ca

Abstract: Despite significant progress made in the overall cure rate, the prognosis for relapsed and refractory malignancies in children remains extremely poor. Hence, there is an urgent need for studies that enable the timely selection of appropriate agents for Phase I clinical studies. The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) is systematically evaluating libraries of known and novel compounds for activity against subsets of high-risk pediatric malignancies with defined molecular aberrations for future clinical development. In this report, we describe the in-vitro activity of a diverse panel of approved oncology drugs against *MLL*-rearranged pediatric leukemia cell lines. Agents in the Approved Oncology Drug Set II (National Cancer Institute/National Institutes of Health Developmental Therapeutics Program) were evaluated by in-vitro cytotoxicity assays in pediatric acute lymphoblastic leukemia and acute myeloid leukemia cell lines with *MLL* gene rearrangements. Validation studies were carried out with patient leukemia cells in culture. Comparative analysis for toxicity against nonmalignant cells was evaluated in normal bone marrow stromal cells and normal human lymphocytes. Results from this study show that 42 of the 89 agents tested have measurable cytotoxicity against leukemia cells, and among these, 12 were effective against all five *MLL*-rearranged cell lines (IC_{50} [half maximal inhibitory concentration] < 1 μ M). These 12 agents include cladribine, dactinomycin, daunorubicin, docetaxel, etoposide, gemcitabine, mitomycin C, mitoxantrone, teniposide, topotecan, triethylenemelamine, and vinblastine. We show that the Approved Oncology Drug Set II contains a number of agents with potent antileukemic activity in the tested cell lines. As approved drugs, these agents have been used in clinical settings for many years for other malignancies, thus their toxicity profile, pharmacokinetics, and other properties are readily available. Further evaluation of their use in future clinical trials for pediatric leukemia with *MLL* abnormalities should be considered.

Keywords: drug screening, therapeutic repertoire

Introduction

Survival rates for acute lymphoblastic leukemia (ALL) have increased dramatically over the last 20 years. Up to 80% of children diagnosed with ALL can be cured with the current treatment regimens.¹ The improvement in cure rate is due to systematic clinical trials with risk stratification of patients during treatment, the institution of intrathecal therapy, the intensification of treatment with existing drugs, and the identification of

better and combinations of chemotherapeutics.² However, the remaining 20% of pediatric patients with leukemia have very poor outcomes with current treatment strategies; these patients often have relapsed or refractory leukemias with distinct molecular abnormalities that categorize them as high-risk.³ The identification of effective therapeutic strategies for these high-risk subgroups remains an important goal for improving survival rates in children with leukemia.

Rearrangement of chromosome band 11q23 at the *MLL* gene (mixed-lineage-leukemia) is common and associated with a particularly poor prognosis for all pediatric age groups presenting with ALL.⁴ The most aggressive forms of *MLL*-rearranged ALL involve balanced translocations at t(4;11), t(11;19), or t(9;11).^{4,5} *MLL* gene rearrangements occur in 80% of children with ALL diagnosed before 1 year of age.^{2,6,7} The t(4;11) or t(11;19) translocations are the most common 11q23 abnormality in infants.⁵ These patients are most often categorized as high- or very high-risk and often experience early treatment failure.^{5–8} The presence of any *MLL*-rearrangement is associated with a significantly poorer prognosis for infants compared with patients whose leukemias possess germ line *MLL*.^{5–7} This also holds true for children who are 1–9 years of age; the presence of t(4;11) or t(9;11) translocations is associated with a poor prognosis compared with other 11q23 abnormalities, such as deletion of 11q23 or different translocations,⁵ or compared with patients with germ line *MLL*.^{4,6} *MLL* gene rearrangements also occur in up to 20% of acute myeloid leukemia (AML) cases and, in general, portend a poor outcome.^{9,10}

Currently, intense strategies such as stem-cell transplantation are needed to treat *MLL*-rearranged acute leukemias, and the outcome still remains poor. Hence, novel therapeutic approaches are urgently needed to improve the outcome in these patients.¹¹ Cell lines derived from leukemia specimens have been instrumental in advancing current knowledge and treatment options in a number of hematological malignancies. Drexler and colleagues have described the utility of cell lines as experimental models for the study of *MLL* gene alterations.¹² It has been hypothesized that such cell lines will help to understand the role of the *MLL* genetic aberration

on the pathogenic process of the disease and will enable the effective identification of agents on a proximate model of the human disease.¹² The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) has established a program to screen cell lines that represent functionally crucial molecular alterations with relevance to currently difficult to cure pediatric malignancies for the purpose of designing future clinical trials. These studies are aimed to provide initial preclinical data to identify drugs with potential that can be further evaluated in mechanistic, drug combination and xenograft studies to facilitate timely development of Phase I studies. In this manuscript, we describe the evaluation of current and novel chemotherapeutic agents using drug panels provided by the National Cancer Institute/National Institutes of Health (NCI/NIH) Developmental Therapeutics Program (DTP). In comparison to currently used chemotherapeutic agents, this screen resulted in the identification of many active agents not typically used in the treatment of pediatric leukemia, providing important data for further studies.

Methods

Tissue culture and cell lines

All cell lines were maintained in OptiMEM I Reduced Serum Media (31985-070, Invitrogen, Carlsbad, CA), supplemented with 10% fetal calf serum and 100 units/mL each of penicillin and streptomycin. Cells were incubated at 37°C with 5% CO₂ buffering. Characteristics of the cell lines are shown in Table 1.

Reagents

The Approved Oncology Drug Set II was obtained from the NCI/NIH DTP Open Chemical Repository.¹³ All agents were solubilized in dimethylsulfoxide (DMSO) (D5879, Sigma Aldrich, Oakville, ON, Canada) at 10 mM stock concentration and stored at –20°C.

Drug screen

The Approved Oncology Drug Set II was screened using KOPN8, SEM, B1, MOLT-3, and TIB-202 cell lines at 10.00, 1.00, 0.10, and 0.01 µM concentrations in duplicate wells of

Table 1 Characteristics of human leukemia cell lines

Cell line	Diagnosis	<i>MLL</i> rearrangement	Age/gender of patient	Reference
SEM	Relapsed preB-ALL	t(4;11)(q21;q23)	5 years/F	Greil et al ⁴³
B1	Relapsed preB-ALL	t(4;11)(q21;q23)	14 years/M	Cohen et al ⁴⁴
KOPN8	preB-ALL	t(11;19)(q23;p13)	3 months/F	Matsuo and Drexler ⁴⁵
MOLT-3	T-ALL	t(4;11)(q21;q23)	19 years/M	Minowada et al ⁴⁶
TIB-202	AML	t(9;11)(p22;q23)	1 year/M	Tsuchiya et al, ⁴⁷ Adati et al ⁴⁸

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; F, female; M, male; preB, precursor B.

96-well plates (655180, Greiner Bio-One, Monroe, NC). Control wells contained an equivalent amount of DMSO. Cells were plated at 5×10^3 cells/well in the presence of drug treatment and incubated at 37°C with 5% CO₂ buffering. After 96 hours, cell numbers were measured by direct cell counting with brightfield analysis using the Celigo™ cytometer¹⁴ (Cytellect Inc, San Diego, CA). Validity of the single round of screening was confirmed by random selection of 11 drugs from the Approved Oncology Drug Set II. These were re-screened as above. The repeated samples closely confirmed the half maximal inhibitory concentration (IC₅₀) values calculated from the first round of screening.

Cell survival assays

A subset of drugs from the Approved Oncology Drug Set II was selected for follow-up analysis. Criteria for selection of these drugs included an IC₅₀ < 1 μM in four cell lines and limited use in current pediatric leukemia treatment protocols. Methotrexate (MTX) and cytarabine (AraC) were also included for comparison. Cells were treated with the drugs as described above, except that triplicate wells were used with 1:10 serial dilutions ranging from 10 μM down to 1×10^{-10} μM. After 96 hours, viable cell numbers were measured by direct cell counting using the Celigo cytometer. Additionally, cell numbers were measured at 24, 48, 72, and 96-hour time points using the Celigo cytometer. The survival percentage was calculated by comparing the number of viable cells in treated wells to control (DMSO)-treated wells.

Normal human samples

Bone marrow stromal (BMS) cells were isolated as previously described¹⁵ and used to evaluate the drug effects on nonleukemic cells. Normal human lymphocytes (NHL) were isolated by Ficoll gradient from whole blood of a healthy volunteer. Cells were treated with the selected Approved Oncology Drug Set II as described above, except that duplicate wells were used with 1:10 serial dilutions ranging from 10 μM down to 1×10^{-6} μM. The characteristics of the NHL and BMS (small size and very flat, respectively) prevented the software for the Celigo cytometer from directly counting these samples. Instead, 5 μL of alamarBlue® (DAL1100, Invitrogen) was added to each well after 96 hours. The cells were incubated an additional 24 hours and then measured at 570 nm and 620 nm using an Opsys MR™ plate reader (Dynex Technologies, Chantilly, VA). Viability data from the alamarBlue assay closely agrees with direct counting by Celigo (Supplemental Figure 1).

Patient samples

Leukemia cells were obtained from samples collected for new therapies for pediatric leukemia research (DC study) following local Institutional Review Board approval and parental consent. Leukemia cells were collected from a 3-month-old male diagnosed with precursor B-ALL (patient 17577; t(11;19)(q23;p13)), an 8-month-old male with precursor B-ALL (patient 87781; t(11;19)(q23;p13)), and a 5-year-old male with T-ALL (patient 41304). Details of the treatment and leukemia cell isolation procedures for patient 17577 are described elsewhere.¹⁶ Isolation procedures for patients 87781 and 41304 were the same as for patient 17577. Patient cells were treated with the selected drugs from the Approved Oncology Drug Set II as described for the BMS cells, except that after 96 hours, cells were counted using the Celigo cytometer.

Calculations and software

All IC₅₀ values were calculated using Microsoft Excel® for Mac 2008 (version 12.2.6) (Microsoft Corporation, Redmond, WA). Heat maps were generated using Mayday computer software (version 1.0).¹⁷

Rationale for model leukemia cell lines

Five different cell lines, all harboring *MLL*-gene rearrangements (Table 1) were tested. The validity of using these cell lines to represent patient samples is confirmed by previous literature where gene expression profiles of ALL cell lines were compared with ALL patient samples.¹⁸ ALL cell lines and patient samples with *MLL* gene rearrangements clustered closely together, demonstrating that cell lines display gene expression profiles comparable to patient samples.¹⁸ The distinguishing feature of cell lines compared with patient samples was higher levels of proliferation-related genes in the cell lines.¹⁸ In addition, other gene expression studies have shown that patient samples with *MLL* gene rearrangements cluster together, further suggesting the similarities of leukemias of this subset.^{19–22} This similar separation of *MLL*-rearranged subsets was also seen in AML.²³ Based upon these previous reports, we performed in-vitro drug screening on the ALL and AML cell lines using the Approved Oncology Drug Set II.

Results

In-vitro activity of microtubule-interfering drugs

All five leukemia cell lines were initially screened with the entire Approved Oncology Drug Set II, which includes most current United States Food and Drug Administration

(FDA)-approved anticancer drugs. For clarity, we have categorized these drugs into the following groups: microtubule-interfering drugs, nucleic acid-targeting drugs, enzyme-inhibitory drugs, receptor- or immuno-modulatory drugs, and miscellaneous drugs.

Drugs that both stabilized and destabilized microtubules had high activity against most of the leukemia cell lines (Figure 1). Studies have shown that the preclinical activity of a drug is correlated to higher Phase II overall response rates of that drug.²³ This means that the greater the potency of a drug (ie, cytotoxicity at low concentrations), the stronger the predictive value for success in Phase II trials.²⁴ High activity is defined as having an IC_{50} less than 1 μ M, which indicates the clinical potential for the drug to effectively inhibit leukemia cell growth at low doses and with few side effects in patients. In TIB-202, KOPN8, SEM, and B1 cells, the IC_{50} values for all four microtubule-interfering drugs (docetaxel, paclitaxel, vinblastine, and vincristine) were less than 0.1 μ M (Figure 1A and Supplemental Table 1). In the T-ALL cell line MOLT-3, there was greater variation in the activity of these microtubule-interfering drugs: paclitaxel and vincristine had no effect (IC_{50} = 10 μ M), whereas docetaxel (IC_{50} < 0.01 μ M) and vinblastine (IC_{50} = 0.851 μ M) were more cytotoxic (Supplemental Table 1). The activity of each drug was compared with MTX or AraC, which are commonly used as therapeutics for pediatric leukemia, by calculating the ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug, within one cell line. The ratios were plotted as a heat map, wherein green indicates higher activity compared with

MTX or AraC, and red indicates lower activity. Figure 1B illustrates the variable sensitivity of MOLT-3 to different microtubule-interfering drugs, and highlights the overall potency of these drugs in the leukemia cells tested. In general, the microtubule-interfering drugs had higher activity than MTX and AraC, although in TIB-202 cells, these drugs were not better than MTX.

In-vitro activity of nucleic acid targeting drugs

The leukemia cell lines were treated with nucleic acid targeting drugs that were further categorized as deoxyribo-nucleic acid (DNA) damaging agents, DNA intercalating agents or nucleic acid synthesis inhibitors (Figure 2 and Supplemental Table 1). None of the DNA damaging agents was particularly active in more than one cell line, as seen by the dominant red coloring of the heat maps (Figure 2B). Mitomycin C, bleomycin, and triethylenemelamine showed moderate activity in some cell lines. Mitomycin C had an IC_{50} value less than 0.5 μ M in all cell lines (Figure 2A and Supplemental Table 1). In contrast, all of the DNA intercalating agents (mitoxantrone, daunorubicin, doxorubicin, and dactinomycin) had high activity for inhibiting the growth of leukemia cell lines and were, in general, more active than MTX and AraC (Figure 2D); the IC_{50} for the majority of these agents was <0.01 μ M (Figure 2C and Supplemental Table 1). Drugs that inhibit nucleic acid synthesis had a wide range of activity against the leukemia cell lines tested. Most of these drugs had little activity, with IC_{50} values above the

Figure 1 IC_{50} and relative effectiveness of microtubule-interfering drugs. **(A)** The IC_{50} (μmol/L) from five leukemia cell lines are shown in a box-whisker plot. For each drug treatment, the vertical lines in each box represent the 25th, 50th, and 75th percentiles, and the horizontal lines represent the minimum and maximum values. IC_{50} values above or below the tested concentration ranges were rounded to the highest or lowest concentration tested, respectively. **(B)** Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC.

Abbreviations: AraC, cytarabine; IC_{50} , half maximal inhibitory concentration; MTX, methotrexate.

Figure 2 IC_{50} and relative effectiveness of nucleic-acid targeting drugs. **(A and B)** DNA damaging agents. **(C and D)** DNA intercalating agents. **(E and F)** Nucleic acid synthesis inhibitors. **(A, C and E)** The IC_{50} ($\mu\text{mol/L}$) from five leukemia cell lines are shown in a box-whisker plot. **(B, D and F)** Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC.

Abbreviations: AraC, cytarabine; DNA, deoxyribonucleic acid; IC_{50} , half maximal inhibitory concentration; MTX, methotrexate.

tested concentration range ($IC_{50} > 10 \mu\text{M}$) (Figure 2E). The exceptions were clofarabine ($IC_{50} < 0.1 \mu\text{M}$ for four of five cell lines), fludarabine ($IC_{50} < 1 \mu\text{M}$ for four of five cell lines), pemetrexed ($IC_{50} < 1 \mu\text{M}$ for four of five cell lines), and gemcitabine ($IC_{50} < 0.05 \mu\text{M}$). Additionally, clofarabine and gemcitabine were more active than MTX and AraC in the respective cell lines (Figure 2F).

In-vitro activity of enzyme-inhibitory drugs

A variety of enzyme-inhibitory drugs from the Approved Oncology Drug Set II were used to treat the leukemia cell lines. These drugs were further categorized based on their enzymatic targets: aromatase, DNA methyltransferase, histone deacetylase, mammalian target of rapamycin (mTOR),

proteasome, topoisomerases, or tyrosine kinases (Figure 3 and Supplemental Table 1). Aromatase inhibitors had little effect on the leukemia cell lines. Not only were the IC_{50} values around 10 μ M (Figure 3A), they were less cytotoxic than MTX and AraC (Figure 3B). The DNA methyltransferase inhibitor azacitidine and the histone deacetylase inhibitor vorinostat had weak activity in most of the cell lines (Figure 3C). Irinotecan was the exception,

However, vorinostat had slightly better activity compared with AraC in KOPN8 and both had superior activity compared with MTX in MOLT-3 (Figure 3D). In contrast, the mTOR inhibitors (everolimus, rapamycin), proteasome inhibitor (bortezomib), and topoisomerase inhibitors (topotecan, etoposide, teniposide) were more potent at inhibiting the leukemia cell lines (Figure 3C). Irinotecan was the exception,

Figure 3 IC_{50} and relative effectiveness of enzyme inhibitory drugs. **(A and B)** Aromatase inhibitors. **(C and D)** DNA methyltransferase, histone deacetylase, mTOR, proteasome, and topoisomase inhibitors. **(E and F)** Tyrosine kinase inhibitors. **(A, C and E)** The IC_{50} (μ mol/L) from five leukemia cell lines are shown in a box-whisker plot. **(B, D and F)** Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC.

Abbreviations: AraC, cytarabine; DNA, deoxyribonucleic acid; IC_{50} , half maximal inhibitory concentration; mTOR, mammalian target of rapamycin; MTX, methotrexate.

which demonstrated lower activity compared with MTX or AraC (Figure 3D). Everolimus, rapamycin, and bortezomib showed greater variation in IC_{50} between cell lines (Figure 3C); however, most of the drugs in these categories were more active than MTX and AraC (Figure 3D). The tyrosine kinase inhibitors appeared to have more cell-specific effects, rather than global effects like some other chemotherapeutic agents (Figure 3E and F). For example, dasatinib, imatinib, and nilotinib showed large variation in the IC_{50} values between the cell lines (Figure 3E). Overall, this category of drugs was less active than MTX and AraC, with some exceptions including dasatinib (Figure 3F). Lapatinib, sorafenib, and sunitinib had

limited potency and were less cytotoxic compared with MTX and AraC (Figure 3E and F).

In-vitro activity of receptor- or immuno-modulatory drugs

Drugs that modulate receptors (epidermal growth factor receptor, estrogen receptor) or the immune response were tested in all five leukemia cell lines (Figure 4A and B). These drugs had little effect on leukemia cell lines, with IC_{50} values $\sim 10 \mu M$ (Figure 4A and Supplemental Table 1). All of these drugs had less activity compared with MTX and AraC, with the exception of MOLT-3 cells, in which these

Figure 4 IC_{50} and relative effectiveness of receptor-modulatory, immuno-modulatory and miscellaneous drugs. **(A and B)** Receptor- and immuno-modulatory drugs. **(C and D)** Miscellaneous drugs. **(A and C)** The IC_{50} ($\mu mol/L$) from five leukemia cell lines are shown in a box-whisker plot. **(B and D)** Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC.

Abbreviations: AraC, cytarabine; IC_{50} , half maximal inhibitory concentration; MTX, methotrexate.

drugs performed equivalently, and erlotinib, which was more active in MOLT-3 cells only (Figure 4B).

In-vitro activity of miscellaneous drugs

A number of drugs from the Approved Oncology Drug Set II that are photo-activated, protective adjuvants or have miscellaneous function were tested in the leukemia cell lines (Figure 4C and D). None of the photo-activated agents or the protective adjuvant drugs had any effect on leukemia cell survival rates ($IC_{50} = 10 \mu M$) (Figure 4C and Supplemental Table 1). Only two drugs in the miscellaneous category, arsenic trioxide and acrichine, had any activity for inhibiting leukemia cell growth. These drugs were cytotoxic only in KOPN8 cells, with IC_{50} values equal to $0.169 \mu M$ and $0.722 \mu M$, respectively (Figure 4C). However, none of these drugs showed higher cytotoxicity compared with MTX or AraC in more than one cell line (Figure 4D).

In-vitro activity of selected candidate drugs in leukemia cell lines

To investigate the possibility that drugs from the Approved Oncology Drug Set II could be translated into therapies for *MLL*-rearranged leukemias, we focused on a subset of drugs from the Approved Oncology Drug Set II for in-depth study. These drugs were included in the initial screen of the Approved Oncology Drug Set II, and were selected due to early indications of potency and diversity of mechanism

of action. Additionally, we included in the analyses two drugs commonly used in pediatric oncology (MTX and AraC) for comparison with the selected drugs. The selected drugs were cladribine (nucleic acid synthesis inhibitor), decitabine (DNA methyltransferase inhibitor), ixabepilone (microtubule stabilizer), plicamycin (DNA intercalating agent), valrubicin (DNA intercalating agent and PKC inhibitor), and vinorelbine (microtubule destabilizer). The mean IC_{50} ($\pm$ standard error) for each drug in SEM, B1, KOPN8, MOLT-3, and TIB-202 cell lines were calculated from two to four experiments with two or three replicate wells per experiment (Table 2).

All of the selected candidate drugs showed significant cytotoxic activity against the leukemia cell lines, although several were less active in MOLT-3 cells than the other four cell lines (Table 2). As was seen for microtubule-interfering drugs (Figure 1), both vinorelbine (Figure 5A) and ixabepilone (Figure 5C) were effective at inhibiting the growth of the leukemia cell lines at low doses. The IC_{50} values were less than $0.425 \mu M$ for all the cell lines except MOLT-3, which was resistant to both of these drugs ($IC_{50} > 10 \mu M$) (Table 2). The nucleic acid-related drugs cladribine (Figure 6A), plicamycin (Figure 6C), valrubicin (Figure 6E), and AraC (Figure 6G) all showed cytotoxicity against leukemia cells. All cell lines tested were sensitive to cladribine, including MOLT-3; however, TIB-202 cells were not sensitive to AraC, and MOLT-3 cells were not sensitive to

Table 2 Mean IC_{50} values after incubation with selected drugs from the Approved Oncology Drug Set II

Drug name (NSC number ^a)	IC_{50} ($\mu mol/L$)				
	Mean ^b $\pm$ SE				
	Cell line				
	SEM	B1	KOPN8	MOLT-3	TIB-202
Cladribine (105014)	$8.85 \times 10^{-2} \pm 3.31 \times 10^{-3}$	$3.45 \times 10^{-1} \pm 3.53 \times 10^{-1}$	$5.44 \times 10^{-2} \pm 1.21 \times 10^{-2}$	$7.95 \times 10^{-1} \pm 1.78 \times 10^{-1}$	$2.63 \times 10^{-1} \pm 2.47 \times 10^{-1}$
Cytarabine (63878)	$2.92 \times 10^{-1} \pm 3.07 \times 10^{-1}$	$1.57 \times 10^0 \pm 1.98 \times 10^0$	$5.78 \times 10^{-1} \pm 4.93 \times 10^{-1}$	$2.96 \times 10^{-1} \pm 2.59 \times 10^{-1}$	$3.49 \times 10^0 \pm 4.08 \times 10^0$
Decitabine (127716)	$>1.00 \times 10^1$	$2.33 \times 10^{-1} \pm 3.08 \times 10^{-1}$	$8.42 \times 10^{-3} \pm 9.51 \times 10^{-4}$	$3.19 \times 10^{-1} \pm 2.38 \times 10^{-1}$	$5.13 \times 10^{-1} \pm 3.05 \times 10^{-1}$
Ixabepilone (747973)	$6.12 \times 10^{-3} \pm 1.09 \times 10^{-3}$	$4.41 \times 10^{-2} \pm 3.05 \times 10^{-2}$	$6.19 \times 10^{-3} \pm 4.05 \times 10^{-3}$	$>1.00 \times 10^1$	$6.64 \times 10^{-2} \pm 3.37 \times 10^{-2}$
Methotrexate (740)	$6.17 \times 10^{-2} \pm 2.90 \times 10^{-2}$	$6.11 \times 10^{-2} \pm 3.55 \times 10^{-2}$	$2.54 \times 10^{-2} \pm 1.80 \times 10^{-2}$	$>1.00 \times 10^1$	$1.41 \times 10^{-1} \pm 4.18 \times 10^{-2}$
Plicamycin (24559)	$2.24 \times 10^{-2} \pm 2.19 \times 10^{-2}$	$5.52 \times 10^{-2} \pm 2.48 \times 10^{-2}$	$1.45 \times 10^{-2} \pm 1.40 \times 10^{-2}$	$7.79 \times 10^0 \pm 3.13 \times 10^0$	$4.47 \times 10^{-2} \pm 4.00 \times 10^{-2}$
Valrubicin (246131)	$4.13 \times 10^{-2} \pm 2.84 \times 10^{-2}$	$1.90 \times 10^{-1} \pm 1.63 \times 10^{-1}$	$6.95 \times 10^{-2} \pm 2.77 \times 10^{-2}$	$3.54 \times 10^0 \pm 4.09 \times 10^0$	$2.95 \times 10^{-1} \pm 2.58 \times 10^{-1}$
Vinorelbine (608210)	$5.40 \times 10^{-2} \pm 2.62 \times 10^{-2}$	$2.70 \times 10^{-1} \pm 2.84 \times 10^{-1}$	$1.95 \times 10^{-2} \pm 8.20 \times 10^{-3}$	$>1.00 \times 10^1$	$4.25 \times 10^{-1} \pm 1.89 \times 10^{-1}$

Notes: ^aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; ^bThe mean IC_{50} was calculated as the average of two–four replicates.

Abbreviations: IC_{50} , half maximal inhibitory concentration; SE, standard error.

Figure 5 Dose response and growth curves of selected microtubule-interfering drugs. Leukemia cell lines were incubated with vinorelbine (**A** and **B**) or ixabepilone (**C** and **D**). (**A** and **C**) Cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with DMSO-treated cells. (**B** and **D**) Cells were incubated with 1 μM of drug and assessed every 24 hours for cell survival compared with DMSO-treated cells.

Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A and C are representative of three separate experiments.

Abbreviation: DMSO, dimethylsulfoxide.

plicamycin and valrubicin (Table 2). Decitabine (Figure 7C) exhibited the greatest variation in activity across the cell lines: KOPN8 cells were the most sensitive (0.00842 μM), followed by B1 cells (0.233 μM), MOLT-3 cells (0.319 μM), and TIB-202 cells (0.513 μM). However, SEM cells appeared to be refractory to this drug ($\text{IC}_{50} > 10 \mu\text{M}$) (Table 2).

We compared the IC_{50} of each selected drug to MTX and AraC (Figure 8). All of the drugs showed superior activity compared with AraC in all cell lines except MOLT-3 cells. Plicamycin and ixabepilone showed the greatest degree of cytotoxicity compared with MTX in four out of five cell lines (ie, IC_{50} values were lower than or equivalent to the IC_{50} of MTX). Vinorelbine was more active than MTX in three of the cell lines, and decitabine and valrubicin were more active than both MTX in two of the cell lines (Figure 8). Cladribine was less active than MTX in all but one cell line (MOLT-3). All of the selected drugs were less potent than MTX in TIB-202 cells, which showed good sensitivity to MTX alone (Figure 8 and Table 2).

Leukemia cell growth rates in the presence of selected candidate drugs

To further characterize the impact of the selected candidate drugs on leukemia cells, we monitored leukemia cell growth over time in the presence of the drugs. As suggested by the IC_{50} values of the microtubule-interfering drugs, vinorelbine (Figure 5B) and ixabepilone (Figure 5D) dramatically inhibited cell growth compared with control-treated cells. After 24 hours exposure to vinorelbine, KOPN8 and TIB-202 cells had half the viable cell numbers (52.3% and 56.3%, respectively) compared with control (Figure 5B). By 96 hours, these values dropped to 10.4% and 12.5% of control, respectively. MOLT-3 cells had a slower decrease in cell numbers, which reached as low as 20.9% by 90 hours. Ixabepilone decreased cell numbers down to 10.8%–23.5% of control numbers after 90 hours (Figure 5D). Similar trends in cell growth were seen for cladribine (Figure 6B), plicamycin (Figure 6D), valrubicin (Figure 6F), AraC (Figure 6H), MTX (Figure 7B), and decitabine (Figure 7D).

Figure 6 Dose response and growth curves of selected nucleic acid-related drugs. Leukemia cell lines were incubated with cladribine (**A** and **B**), plicamycin (**C** and **D**), valrubicin (**E** and **F**), or AraC (**G** and **H**). (**A**, **C**, **E** and **G**) Cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMSO-treated cells. (**B**, **D**, **F** and **H**) Cells were incubated with 1 μM of drug and assessed every 24 hours for cell survival compared with control DMSO-treated cells.

Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A, C, E, and G are representative of three separate experiments.

Abbreviations: AraC, cytarabine; DMSO, dimethylsulfoxide.

Figure 7 Dose response and growth curves of selected enzyme-inhibitory drugs. Leukemia cell lines were incubated with MTX (**A** and **B**) or decitabine (**C** and **D**). (**A** and **C**) Cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMSO-treated cells. (**B** and **D**) Cells were incubated with 1 μM of drug and assessed every 24 hours for cell survival compared with control DMSO-treated cells.

Notes: Data points and error bars are means and standard errors, respectively, of triplicate wells. A and C are representative of three separate experiments.

Abbreviations: DMSO, dimethylsulfoxide; MTX, methotrexate.

Figure 8 Relative effectiveness of selected drugs from the Approved Oncology Drug Set II on leukemia cell lines. Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC_{50} of MTX or AraC to the IC_{50} of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC.

Abbreviations: AraC, cytarabine; IC_{50} , half maximal inhibitory concentration; MTX, methotrexate.

In-vitro activity of selected candidate drugs in patient cells

To determine off-target toxicity effects and the ability of the selected drugs to kill patient leukemia cells, the candidate drugs were also tested on normal bone marrow stromal (BMS) cells, NHL and leukemia cells from infants with *MLL*-rearranged ALL (Table 3). None of the tested drugs had any toxicity effects on NHL or BMS cells and were equivalent in potency as MTX and AraC (Figure 9). Patient 17577 was quite sensitive to a number of the drugs in the selected panel (Figure 10). Cladribine, ixabepilone, plicamycin, valrubicin, and vinorelbine all had IC_{50} values under 1 μM (Table 3 and Figure 10), and were more potent than both MTX and AraC (Figure 9). Ixabepilone was particularly potent against cells from patient 17577, as cell survival dropped to only 32.9% of control-treated cells after 48 hours (Figure 10B). Plicamycin, cladribine, and valrubicin demonstrated similar decreases in cell survival (39.2%, 47.2%, and 46.8%, respectively) after 48 hours (Figure 10D). In contrast, patients 87781 and 41304 were less sensitive to all of the

Table 3 IC₅₀ values after incubation with selected drugs from the Approved Oncology Drug Set II

Drug name	IC ₅₀ (μmol/L)				
	BMS ^b	Normal lymphocyte	Patient 17577	Patient 87781	Patient 41304
Cladribine (105014) ^a	>1.00 × 10 ¹	>1.00 × 10 ¹	2.81 × 10 ⁻¹	7.83 × 10 ¹	>1.00 × 10 ¹
AraC (63878)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	5.30 × 10 ¹	9.26 × 10 ¹
Decitabine (127716)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	4.56 × 10 ¹
Ixabepilone (747973)	>1.00 × 10 ¹	>1.00 × 10 ¹	4.64 × 10 ⁻⁶	>1.00 × 10 ¹	>1.00 × 10 ¹
MTX (740)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	4.20 × 10 ¹
Plicamycin (24559)	>1.00 × 10 ¹	>1.00 × 10 ¹	2.94 × 10 ⁻²	7.44 × 10 ¹	>1.00 × 10 ¹
Valrubicin (246131)	>1.00 × 10 ¹	>1.00 × 10 ¹	3.71 × 10 ⁻¹	4.85 × 10 ¹	>1.00 × 10 ¹
Vinorelbine (608210)	>1.00 × 10 ¹	>1.00 × 10 ¹	3.81 × 10 ⁻³	>1.00 × 10 ¹	>1.00 × 10 ¹

Notes: ^aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; ^bRepresentative of two experiments.

Abbreviations: AraC, cytarabine; BMS, bone marrow stroma; IC₅₀, half maximal inhibitory concentration; MTX, methotrexate.

drugs, although some of the drugs did show better performance compared with MTX and AraC (Figure 9).

Discussion

These data suggest that a number of FDA-approved chemotherapeutic agents have considerable activity against *MLL*-rearranged ALL and AML cell lines and some patient samples. This paper forms part of key pre-clinical groundwork for analysis of these agents as therapy for *MLL*-rearranged leukemia. We suggest that the data found herein form a basis for considering new treatment options for patients with *MLL*-rearranged leukemia following therapy with standard regimens.

We have identified a number of categories of drugs, as well as specific drugs, that are cytotoxic to *MLL*-rearranged cell lines. These include microtubule-interfering drugs, DNA intercalating agents, topoisomerase poisons, mTOR inhibitors, and proteasome inhibitors. In addition to these categories of drugs, some specific agents, such as mitomycin C, gemcitabine, clofarabine, and dasatinib, showed better efficacy than MTX and AraC. Overall, 42 out of the 89 agents tested were potent in at least one leukemia cell line. A total of 12 and 15 of these were potent in five or four cell lines, respectively, with an IC₅₀ less than 1 μM. The twelve agents that were potent in all five cell lines include cladribine, docetaxel, vinblastine, mitomycin C, triethylenemelamine, mitoxantrone, daunorubicin, dactinomycin, gemcitabine, topotecan, etoposide, and teniposide. Some of the drugs, such as cladribine, ixabepilone, valrubicin, plicamycin, and vinorelbine, also performed well in the *MLL*-rearranged patient sample. Overall, this suggests there are a number of agents within the Approved Oncology Drug Set II that could be further evaluated for future clinical trials for *MLL*-rearranged pediatric leukemia.

The most active drugs against the patient sample in this study were cladribine, ixabepilone, valrubicin, plicamycin, and vinorelbine. Cladribine has historically been used for treatment of hairy cell leukemia.²⁵ However, it has also been used to treat several refractory hematological malignancies, including AML.^{26,27} Complete and partial remission (CR and PR) rates were 27% and 32%, respectively, in pediatric AML patients pretreated with cladribine prior to induction therapy.²⁷ Combination therapy of cladribine with AraC in adult AML patients who had relapsed or failed to respond to initial therapy enhanced the effective dose of AraC in the blood by 40% in seven out of nine patients.²⁸ However, cladribine should be used cautiously in patients

Figure 9 Relative effectiveness of selected drugs from the Approved Oncology Drug Set II on normal and patient samples. Heat map of drug effectiveness compared with MTX or AraC. Values are a ratio of the IC₅₀ of MTX or AraC to the IC₅₀ of each drug. Green, black, and red represent superior, equivalent, and inferior activity, respectively, to MTX or AraC. 17577, 87781, and 41304 represent the patient samples.

Abbreviations: AraC, cytarabine; BMS, bone marrow stroma; IC₅₀, half maximal inhibitory concentration; MTX, methotrexate; NHL, normal human lymphocytes.

Figure 10 Dose response and growth curves of selected drugs with patient 17577 leukemia cells. Cells isolated from patient 17577 were incubated with the indicated drugs. **(A and C)** Cells were incubated with varying concentrations of drugs and assessed after 96 hours for survival compared with control DMSO-treated cells. **(B and D)** Cells were incubated with 1 μ M of drug and assessed every 24 hours for cell survival compared with control DMSO-treated cells.

Note: Data points and error bars are means and standard errors, respectively, of triplicate wells.

Abbreviations: AraC, cytarabine; DMSO, dimethylsulfoxide; MTX, methotrexate.

with renal dysfunction, as demonstrated by a case study of a pediatric AML patient treated with cladribine for 5 days.²⁹ These previous studies, along with the data in this paper, suggest some potential for cladribine during treatment of *MLL*-rearranged pediatric leukemia, as has been used anecdotally for a number of years, often when combined with etoposide.

The microtubule-interfering drugs produced promising results in this study. Vinorelbine, in combination with topotecan, thiotepa, dexamethasone, and gemcitabine, has been used to treat patients with relapsed or refractory acute leukemia.³⁰ In one study, 36% of pediatric patients achieved CR and 11% achieved PR on this regimen.³⁰ In another study, 37% of adult patients with refractory ALL achieved CR with a similar regimen.³¹ Ixabepilone is a new generation microtubule stabilizer that has mainly been used for metastatic breast cancer therapy in patients with few treatment options.³² It has also been used in a Phase II trial of patients with a variety of treatment-refractory sarcomas, malignant peripheral nerve sheath tumors, neuroblastoma, and Wilms tumors.³³ Considering the

potency of the microtubule-interfering agents in this study and others,³⁴ and the prominent use of vincristine in current leukemia treatment protocols, vinorelbine and ixabepilone are reasonable candidates for further consideration in *MLL*-rearranged leukemias.

Valrubicin is a derivative of doxorubicin, an anthracycline antibiotic with DNA intercalation abilities. Valrubicin has only been used for treatment of bladder cancer³⁵ and topical application of developing skin tumors.³⁶ Although, not previously used in leukemia patients, the effectiveness of valrubicin in cell lines and the patient sample suggest it for further analysis as a new therapeutic for *MLL*-rearranged leukemia.

Some of the agents tested in these experiments have been used for leukemia or lymphoma treatment already, although they are not part of typical frontline treatment regimens. For example, decitabine has gained increasing attention in leukemia and myelodysplastic syndrome settings.^{37,38} In Phase II studies of decitabine in combination with clofarabine and low-dose AraC, 59% of elderly patients with AML achieved

CR with manageable toxicity profiles.³⁹ In adult patients with refractory AML, CR was achieved in 34% of patients who received decitabine therapy.⁴⁰ POETIC is currently conducting a Phase I study of decitabine in combination with AraC, daunorubicin, and etoposide chemotherapy for newly diagnosed patients with AML. Plicamycin has also been used, in combination with interferon- α or hydroxyurea, to treat patients with chronic myeloid leukemia (CML) and myeloid blast crisis.⁴¹ This treatment regimen has had limited success in CML or AML therapy. Three of thirteen patients with CML had PR or CR, while two became stabilized on treatment.⁴¹ The median survival of these patients increased to 24 months from previously reported 6-month median survival.⁴¹ A Phase II study of plicamycin and hydroxyurea in patients with high-risk, relapsed, or refractory AML resulted in no patients with CR or PR, and considerable toxicity.⁴² These data suggest some caution against selecting plicamycin for clinical trial evaluation in pediatric patients with *MLL*-rearranged leukemia.

In this report, we have attempted to identify agents that show effective in-vitro cytotoxicity against malignant cells and cell lines derived from patients with refractory leukemia. However, the spectrum of effective agents includes drugs that have acceptable toxicities, as well as those that carry the potential to induce molecular abnormalities with increased risk of secondary malignancies in the future. In deciding future clinical application of any selected agent, the benefit of inducing remission in a highly refractory malignancy should be carefully considered against the risk of such possibilities. Similarly, we have based their activity profiles largely on IC_{50} values. Although lower IC_{50} values are generally considered to suggest effectiveness against neoplastic cells, it does not necessarily mean it would be the most applicable clinically because of untested toxicity in the patient. Utilization of the information presented in this paper should take into consideration, particularly in heavily pretreated children, the potential adverse effects such as neurotoxicity, hepatotoxicity, and nephrotoxicity. Taken together, the results from this study highlight potential alternative therapeutic options for *MLL*-rearranged leukemias. The data presented herein demonstrate the need for further characterization of these drugs, either as single agents or in effective combination with novel targeted agents, for possible future clinical trials.

Acknowledgments

This work was supported by grants from the Kids Cancer Care Foundation of Alberta and the Alberta Children's

Hospital Foundation. RJA was funded in part through an endowed King Fahd Chair.

Disclosure

The authors have no conflicts of interest to declare.

References

1. Pui C-H, Evans WE. Acute lymphoblastic leukemia. *N Engl J Med*. 1998;339:605–615.
2. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. *Hematol Oncol Clin North Am*. 2010;24:1–18.
3. Biondi A, Cimino G, Pieters R, Pui C-H. Biological and therapeutic aspects of infant leukemia. *Blood*. 2000;96:24–33.
4. Behm FG, Raimondi SC, Freestadt JL, et al. Rearrangement of the *MLL* gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. *Blood*. 1996;87:2870–2877.
5. Pui C-H, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. *Lancet*. 2002;359:1909–1915.
6. Chen CS, Sorensen PH, Reaman GH, et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcomes. *Blood*. 1993;81:2386–2393.
7. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of *HRX* rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood*. 1994;84:570–573.
8. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. *Blood*. 2006;108:441–451.
9. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. *Hematol Oncol Clin North Am*. 2010;24:35–63.
10. Martens JHA, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. *FEBS Lett*. 2010;584:2662–2669.
11. Tamai H, Inokuchi K. 11q23/*MLL* acute leukemia: update of clinical aspects. *J Clin Exp*. 2010;50:91–98.
12. Drexler HG, Quentmeier H, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of *MLL* gene alterations. *Leukemia*. 2004;18:227–232.
13. Development Therapeutics Program [homepage on the Internet]. NCI/NIH. Available from: <http://dtp.cancer.gov>. Accessed July 23, 2011.
14. Nabzdyk CS, Chun M, Pradhan L, LoGerfo FW. High throughput RNAi assay optimization using adherent cell cytometry. *J Transl Med*. 2011;9:48–56.
15. Narendran A, Ganjavi H, Morson N, et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. *Exp Hematol*. 2003;31:693–701.
16. Jayanthan A, Incoronato A, Singh A, et al. Cytotoxicity, drug combinability, and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with *MLL* rearrangements. *Pediatr Blood Cancer*. 2011;56:353–360.
17. Battke F, Symons S, Nieselt K. Mayday – integrative analytics for expression data. *BMC Bioinformatics*. 2010;11:121–130.
18. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. *Blood*. 2004;103:1043–1049.
19. Armstrong SA, Staunton JE, Silverman LB, et al. *MLL* translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat Genet*. 2002;30:41–47.
20. Yeoh E-J, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. *Cancer Cell*. 2002;1:133–143.
21. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. *Blood*. 2003;102:2951–2959.

22. Anderssen A, Eden P, Olofsson T, et al. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. *BMC Med Genomics*. 2010;3:6–14.
23. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. *Blood*. 2004;104:3679–3687.
24. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. *Clin Cancer Res*. 2003;9:4227–4239.
25. Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. *Blood*. 2010;116:2884–2896.
26. Santana VM, Hurwitz Ca, Blakely RL et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. *Blood*. 1994;84:1237–1242.
27. Santana VM, Mirro J Jr, Keams C, Schell MJ, Crom W, Blakley RL. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. *J Clin Oncol*. 1992;10:364–370.
28. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. *Blood*. 1996;87:256–264.
29. Crews KR, Wimmer PS, Hudson JQ, Howard SC, Ribeiro RC, Razzouk BI. Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. *J Pediatr Hematol Oncol*. 2002;24:677–680.
30. Kolb EA, Steinherz PG. A new multidrug induction protocol with topotecan, vinorelbine, thiotepe, dexamethasone and gemcitabine for relapsed or refractory acute leukemia. *Leukemia*. 2003;17:1967–1972.
31. Hiwarkar P, Arkenau H-T, Treleaven J, Morgan G, Potter M, Ethell M. The feasibility of using topotecan, vinorelbine, thiotepe and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma. *Leukemia*. 2008;22:1627–1629.
32. Egerton N. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer. *Cancer Chemoth Pharm*. 2010;66:1005–1012.
33. Jacobs S, Fox E, Krailo M, et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. *Clin Cancer Res*. 2010;16:750–754.
34. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. *Pediatr Blood Cancer*. 2011;56:239–249.
35. Lamm DL, McGee WR, Hale K. Bladder cancer: current optimal intravesical treatment. *Urol Nurs*. 2005;25:323–332.
36. Andersen SM, Rosada C, Dagnaes-Hansen F, et al. Topical application of valrubicin has a beneficial effect on developing skin tumors. *Carcinogenesis*. 2010;31:1483–1490.
37. Ravandi F, Issa J-P, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. *Cancer*. 2009;115:5746–5751.
38. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. *Drugs*. 2010;70:1381–1394.
39. Parikh SA, Hagop K, Garcia-Manero G, et al. Clofarabine plus low-dose cytarabine induction followed by consolidation with clofarabine plus low-dose cytarabine alternating with decitabine as frontline therapy for patients (pts) with acute myeloid leukemia (AML) = 60 years (yrs). *Blood*. 2009;114:Abstract No. 2058.
40. Ritchie EK, Arnason J, Feldman EJ, et al. Decitabine-based salvage therapy in adults with acute myeloid leukemia. *Blood*. 2009;114:Abstract No. 2063.
41. Dutcher JP, Coletti D, Paietta E, Wiernik PH. A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. *Leuk Res*. 1997;21:375–342.
42. Archimbaud E, Troncy J, Sebban C, et al. Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. *Cancer Chemoth Pharm*. 1989;25:223–225.
43. Greil J, Gramatzki M, Burger R, et al. The acute lymphoblastic leukemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. *Br J Haematol*. 1994;86:275–283.
44. Cohen A, Brunberger T, Vanek W, et al. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotypic leukemic cell line. *Blood*. 1991;78:94–102.
45. Matsuo Y, Drexler HG. Establishment and characterization of human B cell precursor-leukemia cell lines. *Leuk Res*. 1998;22:567–579.
46. Minowada J, Ohnuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. *J Natl Cancer I*. 1972;49:891–894.
47. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). *Int J Cancer*. 1980;26:171–176.
48. Adati N, Huang M-C, Suzuki T, Suzuki H, Kojima T. High-resolution analysis of aberrant regions in autosomal chromosomes in human leukemia THP-1 cell line. *BMC Res Notes*. 2009;2:153–159.

Supplementary material

Figure S1 Comparison of cell survival measurements by the Celigo™ cytometer and alamarBlue®. W1 leukemia cells were incubated with imatinib (A), gefitinib (B), sorafenib (C), or sunitinib (D) for 96 hours then measured using the Celigo cytometer, followed by alamarBlue. Survival compared with control DMSO-treated cells is shown, with data points and error bars representing the mean and standard error, respectively.

Abbreviation: DMSO, dimethylsulfoxide.

Table S1 IC₅₀ values after incubation with drugs from the Approved Oncology Drug Set II

Drug name (NSC number ^a)	IC ₅₀ (μmol/L)				
	Cell line				
	SEM	BI	KOPN8	MOLT-3	TIB-202
Microtubule stabilizers^b					
Docetaxel (628503)	$<1.00 \times 10^{-2}$	2.78×10^{-4}	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	5.88×10^{-2}
Paclitaxel (125973)	$<1.00 \times 10^{-2}$	$8.04 \times 10^{-2} \pm 3.49 \times 10^{-2}$	$<1.00 \times 10^{-2}$	1.00×10^1	1.06×10^{-1}
Microtubule destabilizers					
Vinblastine (49842)	1.00×10^{-2}	9.93×10^{-4}	$<1.00 \times 10^{-2}$	8.51×10^{-1}	8.79×10^{-3}
Vincristine (67574)	$<1.00 \times 10^{-2}$	4.42×10^{-2}	$<1.00 \times 10^{-2}$	1.00×10^1	4.02×10^{-2}
DNA damaging agents					
Altretamine (13875)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Bleomycin (125066)	$<1.00 \times 10^{-2}$	$2.92 \times 10^0 \pm 2.23 \times 10^0$	1.08×10^{-1}	8.42×10^0	$1.07 \times 10^0 \pm 1.84 \times 10^{-1}$
Busulfan (750)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	6.36×10^0	$>5.00 \times 10^0$
Carboplatin (241240)	$>1.00 \times 10^1$	7.73×10^0	5.14×10^0	6.97×10^0	7.64×10^0
Carmustine (409962)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Chlorambucil (3088)	7.29×10^0	6.41×10^0	3.38×10^0	5.56×10^0	4.47×10^0
Cisplatin (119875)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Cyclophosphamide (26271)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Dacarbazine (45388)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Estramustine (702294)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Ifosfamide (109724)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Lomustine (79037)	9.35×10^0	8.32×10^0	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Melphalan (8806)	5.80×10^0	4.08×10^0	4.25×10^{-1}	1.03×10^0	2.20×10^0
Mitomycin C (26980)	5.04×10^{-2}	$3.71 \times 10^{-1} \pm 5.56 \times 10^{-2}$	$5.94 \times 10^{-2} \pm 4.38 \times 10^{-2}$	2.21×10^{-2}	$8.55 \times 10^{-2} \pm 6.02 \times 10^{-2}$
Nitrogen mustard (762)	8.83×10^{-1}	9.58×10^{-1}	1.99×10^0	$>1.00 \times 10^1$	3.42×10^0
Oxaliplatin (266046)	5.67×10^0	3.68×10^0	3.09×10^{-1}	9.69×10^{-1}	6.20×10^0
Pipobroman (25154)	4.32×10^0	2.63×10^0	3.89×10^{-1}	6.35×10^0	4.34×10^0
Procarbazine (77213)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Streptozocin (85998)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Temozolomide (362856)	9.12×10^0	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Thiotepa (6396)	3.78×10^0	6.38×10^0	1.96×10^0	3.01×10^0	5.00×10^0

(Continued)

Table S1 (Continued)

Drug name (NSC number ^a)	IC ₅₀ (μmol/L)				
	Cell line				
	SEM	BI	KOPN8	MOLT-3	TIB-202
Triethylenemelamine (9706)	4.81×10^{-1}	3.97×10^{-1}	1.97×10^{-1}	2.60×10^{-1}	4.47×10^{-1}
Uracil mustard (34462)	4.85×10^0	3.65×10^0	2.22×10^0	9.66×10^0	2.70×10^0
DNA intercalating agents					
Dactinomycin (3053)	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-10}$	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-5}$
Daunorubicin (82151)	$<1.00 \times 10^{-2}$	$9.45 \times 10^{-3} \pm 1.92 \times 10^{-3}$	$<5.00 \times 10^{-3}$	$<1.00 \times 10^{-2}$	1.08×10^{-2}
Doxorubicin (123127)	$<1.00 \times 10^{-2}$	$1.20 \times 10^{-1} \pm 1.41 \times 10^{-1}$	$<1.00 \times 10^{-2}$	7.84×10^0	5.85×10^{-2}
Mitoxantrone (279836)	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	3.42×10^{-1}	$<1.00 \times 10^{-2}$
Nucleic acid synthesis inhibitors					
Capecitabine (712807)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Clofarabine (606869)	2.58×10^{-2}	$<1.00 \times 10^{-2}$	8.70×10^{-3}	$>1.00 \times 10^1$	$<1.00 \times 10^{-2}$
Floxuridine (27640)	$>1.00 \times 10^1$	8.48×10^0	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Fludarabine (312887)	8.87×10^{-2}	9.09×10^{-2}	7.05×10^{-2}	$>1.00 \times 10^1$	7.31×10^{-2}
Fluorouracil (19893)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	7.11×10^0	$>5.00 \times 10^0$
Gemcitabine (613327)	$<1.00 \times 10^{-2}$	$2.57 \times 10^{-2} \pm 1.03 \times 10^{-2}$	$<5.00 \times 10^{-3}$	$<1.00 \times 10^{-2}$	$5.65 \times 10^{-2} \pm 7.28 \times 10^{-2}$
Hydroxyurea (32065)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Mercaptopurine (755)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Nelarabine (686673)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	1.23×10^0	$>1.00 \times 10^1$
Pemetrexed (698037)	$>1.00 \times 10^1$	6.71×10^{-1}	1.58×10^{-1}	5.67×10^{-1}	1.79×10^{-1}
Pentostatin (218321)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Thioguanine (752)	9.38×10^{-1}	8.77×10^0	4.50×10^0	7.05×10^0	5.20×10^0
Aromatase inhibitors					
Anastrozole (719344)	2.08×10^0	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Exemestane (713563)	2.08×10^0	$>1.00 \times 10^1$	8.89×10^0	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Letrozole (719345)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
DNA methyltransferase inhibitors					
Azacitidine (102816)	1.30×10^0	5.07×10^0	8.36×10^{-1}	6.21×10^0	5.20×10^0
Histone deacetylase inhibitors					
Vorinostat (701852)	$>1.00 \times 10^1$	3.82×10^0	4.16×10^{-1}	5.67×10^{-1}	4.30×10^0
mTOR inhibitors					
Everolimus (733504)	$<1.00 \times 10^{-2}$	8.34×10^{-1}	$<1.00 \times 10^{-2}$	$>1.00 \times 10^1$	$<1.00 \times 10^{-2}$

(Continued)

Table S1 (Continued)

Drug name (NSC number ^a)	IC ₅₀ (μmol/L)				
	Cell line				
	SEM	BI	KOPN8	MOLT-3	TIB-202
Rapamycin (226080)	$<1.00 \times 10^{-2}$	8.04×10^{-3}	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	$7.05 \times 10^0 \pm 4.17 \times 10^0$
Proteasome inhibitors					
Bortezomib (681239)	$<1.00 \times 10^{-2}$	3.97×10^{-3}	$<1.00 \times 10^{-2}$	$>1.00 \times 10^1$	5.71×10^{-3}
Tyrosine kinase inhibitors					
Dasatinib (732517)	4.05×10^0	$<1.00 \times 10^{-6}$	7.48×10^{-3}	$>1.00 \times 10^1$	$<1.00 \times 10^{-6}$
Imatinib (743414)	7.68×10^0	$2.06 \times 10^{-1} \pm 1.34 \times 10^{-2}$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$2.70 \times 10^{-1} \pm 3.07 \times 10^{-1}$
Lapatinib (745750)	4.73×10^0	5.70×10^0	5.20×10^0	$>1.00 \times 10^1$	7.42×10^0
Nilotinib (747599)	$>1.00 \times 10^1$	$<1.00 \times 10^{-2}$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$<1.00 \times 10^{-2}$
Sorafenib (747971)	1.54×10^0	5.66×10^0	3.86×10^0	9.63×10^0	5.95×10^0
Sunitinib (750690)	1.35×10^{-1}	5.36×10^0	3.30×10^0	$>1.00 \times 10^1$	3.29×10^0
Topoisomerase poisons					
Etoposide (141540)	9.28×10^{-2}	$7.10 \times 10^{-1} \pm 5.81 \times 10^{-1}$	1.97×10^{-2}	1.07×10^{-1}	$4.56 \times 10^{-1} \pm 3.12 \times 10^{-1}$
Irinotecan (616348)	3.40×10^0	2.29×10^0	1.69×10^0	3.92×10^0	2.53×10^0
Teniposide (122819)	9.28×10^{-3}	$2.98 \times 10^{-2} \pm 3.09 \times 10^{-2}$	1.80×10^{-4}	1.17×10^{-2}	$4.91 \times 10^{-2} \pm 3.08 \times 10^{-2}$
Topotecan (609699)	$<1.00 \times 10^{-2}$	$2.76 \times 10^{-2} \pm 3.85 \times 10^{-2}$	$<1.00 \times 10^{-2}$	$<1.00 \times 10^{-2}$	4.53×10^{-2}
EGFR inhibitors					
Erlotinib (718781)	1.00×10^0	2.98×10^0	5.82×10^0	5.70×10^0	6.68×10^0
Gefitinib (715055)	4.89×10^0	5.16×10^0	5.08×10^0	$>1.00 \times 10^1$	9.28×10^0
Estrogen receptor modulators					
Fulvestrant (719276)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	7.64×10^0	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Raloxifene (747974)	4.44×10^0	$>1.00 \times 10^1$	8.30×10^0	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Tamoxifen (180973)	$>1.00 \times 10^1$	6.45×10^0	2.70×10^0	1.00×10^1	$>5.00 \times 10^0$
Immunomodulatory agents					
Imiquimod (369100)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	2.90×10^0	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Lenalidomide (747972)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	1.00×10^1	$>1.00 \times 10^1$
Thalidomide (66847)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Photo-activated agents					
Aminolevulinic acid (18509)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>1.00 \times 10^1$
Methoxsalen (45923)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$
Protective adjuvant drugs					
Allopurinol (1390)	$>1.00 \times 10^1$	$>1.00 \times 10^1$	$>5.00 \times 10^0$	$>1.00 \times 10^1$	$>5.00 \times 10^0$

(Continued)

Table S1 (Continued)

Drug name (NSC number ^a)	IC ₅₀ (μmol/L)				
	Cell line				
	SEM	BI	KOPN8	MOLT-3	TIB-202
Amifostine (296961)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹
Dexrazoxone (169780)	>1.00 × 10 ¹	>1.00 × 10 ¹	>5.00 × 10 ⁰	>1.00 × 10 ¹	>5.00 × 10 ⁰
Zoledronic acid (721517)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹
Miscellaneous drugs					
Acrichine (14229)	6.40 × 10 ⁰	4.63 × 10 ⁰	7.22 × 10 ⁻¹	4.07 × 10 ⁰	4.50 × 10 ⁰
Arsenic trioxide (92859)	>1.00 × 10 ¹	>1.00 × 10 ¹	1.69 × 10 ⁻¹	>1.00 × 10 ¹	>1.00 × 10 ¹
Celecoxib (719627)	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹	>1.00 × 10 ¹
Megestrol acetate (71423)	>1.00 × 10 ¹	>1.00 × 10 ¹	>5.00 × 10 ⁰	>1.00 × 10 ¹	>5.00 × 10 ⁰
Mitotane (38721)	>1.00 × 10 ¹	>1.00 × 10 ¹	>5.00 × 10 ⁰	>1.00 × 10 ¹	>5.00 × 10 ⁰
Tretinoin (122758)	>1.00 × 10 ¹	>1.00 × 10 ¹	>5.00 × 10 ⁰	>1.00 × 10 ¹	>5.00 × 10 ⁰

Notes: ^aCompound identification number in the National Cancer Institute/National Institutes of Health Developmental Therapeutics Program database; ^bSome drugs may have more than one mechanism of action.

Abbreviation: IC₅₀, half maximal inhibitory concentration.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/ontargets-and-therapy-journal>